Valuation: DNAPrint Genomics, Inc.

Market Cap 2.58M 2.26M 2.14M 1.95M 3.65M 247M 3.67M 25.57M 9.9M 126M 9.68M 9.47M 406M P/E 2005
-0.23x
P/E 2006 -0.27x
Enterprise Value 1.36M 1.2M 1.13M 1.03M 1.93M 131M 1.94M 13.53M 5.24M 66.78M 5.12M 5.01M 215M EV / Sales 2005
1.89x
EV / Sales 2006 1.06x
Free-Float
100%
Yield 2005 *
-
Yield 2006 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 0
0
Manager TitleAgeSince
Director of Finance/CFO - 2009-12-22
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.29K
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.08%+2.12%+62.67%+145.08% 27B
Weighted average by Cap. +0.11%+2.86%+79.67%+160.28%

Financials

2005 2006
Net sales 1.28M 1.12M 1.06M 963K 1.8M 122M 1.82M 12.65M 4.9M 62.46M 4.79M 4.69M 201M 2.43M 2.13M 2.02M 1.84M 3.44M 233M 3.46M 24.13M 9.35M 119M 9.13M 8.94M 383M
Net income -8.72M -7.65M -7.22M -6.58M -12.32M -835M -12.41M -86.44M -33.48M -427M -32.72M -32.02M -1.37B -12.35M -10.84M -10.23M -9.33M -17.46M -1.18B -17.58M -122M -47.43M -605M -46.36M -45.36M -1.94B
Net Debt -737K -646K -611K -556K -1.04M -70.61M -1.05M -7.31M -2.83M -36.07M -2.77M -2.71M -116M -1.21M -1.07M -1.01M -917K -1.72M -116M -1.73M -12.05M -4.67M -59.47M -4.56M -4.46M -191M
Logo DNAPrint Genomics, Inc.
DNAPrint genomics, Inc. is a development-stage pharmaceutical company. As of March 15, 2007, the Company’s pharmacogenomics products were still in development. The Company generates revenues in its consumer, forensic and genotyping services, but these services have not resulted in the generation of significant revenues. During the year ended December 31, 2006, the Company’s revenues were from the sales of its ancestry product, AncestryByDNA and genotyping services. The Company provides services that range from sequencing and genotyping to the entire process of single nucleotide polymorphisms (SNP) discovery to large industrial customers. Contract genotyping is the process of reading a genetic sequence and identifying differences in the sequence letters. This information helps researchers understand how human differences are expressed at the gene level.
Employees
25
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. DNAG Stock